{"id":399563,"date":"2026-04-19T02:26:10","date_gmt":"2026-04-19T02:26:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/399563\/"},"modified":"2026-04-19T02:26:10","modified_gmt":"2026-04-19T02:26:10","slug":"how-the-idorsia-swxidia-story-is-shifting-as-price-targets-and-risks-reset","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/399563\/","title":{"rendered":"How The Idorsia (SWX:IDIA) Story Is Shifting As Price Targets And Risks Reset"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.<\/p>\n

Idorsia\u2019s analyst story has shifted again, with a new CHF 5 price target sitting alongside an unchanged fair value estimate of CHF 4.5. This reset reflects a mix of confidence in the company\u2019s assets and concern around higher operating expenses and execution risks, as highlighted in recent analyst commentary. As you read on, you will see how these changing targets shape the evolving narrative and what to watch if you are tracking the stock.<\/p>\n

Stay updated as the Fair Value for Idorsia<\/a> shifts by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Idorsia.<\/p>\n

H.C. Wainwright maintains a Buy rating on Idorsia, signaling that, despite recent adjustments, the firm still sees the current share price as offering potential upside relative to its analysis.<\/p>\n

The new CHF 5 price target from H.C. Wainwright sits slightly above the referenced fair value estimate of CHF 4.5, which suggests the analyst still factors in some value for Idorsia\u2019s pipeline and future execution, even with increased uncertainty.<\/p>\n

H.C. Wainwright cut its price target to CHF 5 from CHF 6, pointing to reduced forward visibility, which tells you that earnings and cash flow expectations are now viewed as less predictable.<\/p>\n

The same report highlights higher operating expenses, which can pressure profitability and may limit flexibility if revenue does not keep pace, adding another layer of execution risk for investors to monitor.<\/p>\n

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!<\/a><\/p>\n

\"SWX:IDIA<\/a> SWX:IDIA 1-Year Stock Price Chart <\/p>\n

We’ve flagged 5 risks for Idorsia. See which could impact your investment.<\/a><\/p>\n

Idorsia reported positive Phase 2 top line results for daridorexant in pediatric insomnia, with a statistically significant dose dependent improvement in total sleep time and additional gains on multiple sleep measures in patients aged 10 to under 18 years.<\/p>\n

Phase 2 pediatric data for daridorexant indicate an excellent safety and tolerability profile up to the 50 mg adult dose, with no signals of abuse or withdrawal and inclusion of patients with neurodevelopmental disorders such as ASD and ADHD.<\/p>\n

Idorsia plans to engage with health authorities on next steps for pediatric insomnia and a potential new investigation pathway in children with neurodevelopmental disorders. Full daridorexant data will be shared at future congresses and in peer reviewed publications.<\/p>\n

The FDA agreed that the Phase 3 registration program for lucerastat in Fabry disease will center on renal outcomes. This builds on MODIFY Phase 3 and extension data that report robust and sustained reductions in Fabry related biomarkers and a supportive renal signal in pursuit of market authorization for an oral treatment option.<\/p>\n

Story Continues <\/p>\n

Fair value remains at CHF 4.5, with the updated estimate unchanged from the prior figure.<\/p>\n

Revenue growth assumption is kept at around 21.57%, in line with the previous view.<\/p>\n

Net profit margin is updated from roughly 12.88% to about 14.42%.<\/p>\n

Future P\/E is adjusted from about 32.72x to roughly 29.19x.<\/p>\n

The discount rate is adjusted slightly from 6.53% to about 6.50%.<\/p>\n

Narratives link a company’s scientific and commercial story to the financial assumptions behind revenue, margins, and fair value. They refresh as new data, guidance, and pricing information come through so you can see how the thesis is evolving in real time.<\/p>\n

Head over to the Simply Wall St Community and follow the Narrative on Idorsia<\/a> to stay up to date on:<\/p>\n

How expectations around QUVIVIQ reimbursement, global rollout, and a possible U.S. DORA descheduling are feeding into revenue assumptions.<\/p>\n

What TRYVIO’s entry into resistant hypertension and the broader Fabry and pediatric programs could mean for Idorsia’s long term product mix.<\/p>\n

Key risks around unproven drug uptake, tighter drug pricing controls, and the funding and cost profile needed to reach the profitability timeline outlined by analysts.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include IDIA.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":232133,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,106601,11628,189375,85,46,25582,130782],"class_list":{"0":"post-399563","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-business","9":"tag-chf","10":"tag-fair-value","11":"tag-idorsia","12":"tag-il","13":"tag-israel","14":"tag-price-target","15":"tag-simply-wall-st"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/399563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=399563"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/399563\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/232133"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=399563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=399563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=399563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}